Optimal timing maximizes Paxlovid benefits for treating COVID-19
Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit ...
Who needs Paxlovid now? New guidelines suggest only highest-risk groups should get COVID drug
There are new Canadian recommendations for who should actually get Paxlovid at this point, guided by a growing body of ...
Pulse1d
BMA workload warning as ICBs want GPs to take over Covid antiviral prescribing
The BMA has received ‘many reports’ of ICBs considering decommissioning specialist Covid antiviral services and passing the ...
Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations ...
Scientific American15d
Paxlovid COVID Treatment Is Most Beneficial for Unvaccinated People with Risk Factors. Others May Not Need It
The novel antiviral drug Paxlovid swiftly entered the U.S. pharmaceutical market in late 2021 as an emergency treatment for people who were vulnerable to severe COVID complications. By May 2023 ...
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...
Taiwan News20h
Antiviral Combination Therapies Market Seizing Tomorrow Harnessing the Power of Future Market Size Trends
Antiviral Combination Therapies Market is valued approximately USD 40.4 billion in 2019 and is anticipated to grow with a healthy growth rate of more than $ over the forecast period 2020-2027.
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms 1. David Cutler, PhD, a professor of economics at Harvard University, estimates in a recent research disclosure that the ...